5 strategies for overcoming challenges to CAR-T cells in solid tumours with CAR-T cells
It’s time to talk about tackling solid tumours with CAR-T cell therapies. In the past, this has been a challenging area with few or modest responses seen in people with advanced cancers.
As researchers go back to basics and think about both improving on the CAR construct design as well as fine tuning of the various elements, I am pleased to say things are finally looking a bit more upbeat on both sides of the pond.
Here we describe five very different strategies research groups are taking with a variety of different solid tumour targets and cancer types.
Some of these examples are already being evaluated in early stage studies in the clinic, while others have gone through their paces in terms of optimising performance and are about to head in this direction…
BSB subscribers can read our latest commentary – you can either log-in or click to access.
This content is restricted to subscribers
We’ve written extensively about various cellular therapy approaches in hematologic malignancies involving T cells and natural killer (NK) cells over the last few years, but if we are to see significant lasting success in solid tumours then we may need to consider the involvement of other immune cells.